(Q36727064)

15 August 2017

1 reference

title

Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? (English)

1 reference

15 August 2017

W Arns

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Transplantation Proceedings

15 August 2017

published in

1 reference

15 August 2017

volume

39

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

88-93

1 reference

Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Antiviral and cytotoxic effects of mycophenolic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Treatment Of Psoriasis With Oral Mycophenolic Acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Clinical pharmacokinetics of mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Mycophenolate mofetil-induced villous atrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Active pyrimidine absorption by chicken colon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Influence of hexobendine, dipyridamole, dilazep, lidoflazine, inosine and purine riboside on adenosine uptake by the isolated epithelium of guinea pig jejunum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Adenosine uptake by the isolated epithelium of guine pig jejunum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Absorption characteristics of EC-MPS--an enteric-coated formulation of mycophenolic sodium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Carboxyl nonsteroidal anti-inflammatory drugs are efficiently glucuronidated by microsomes of the human gastrointestinal tract.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Acyl glucuronide reactivity in perspective: biological consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

Bioavailability improvement of mycophenolic acid through amino ester derivatization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

RS-61443--a new, potent immunosuppressive agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2006.10.189

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TRANSPROCEED.2006.10.189

1 reference

release_coa4buznm5cpvlwwpoxtjeyisa

15 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/coa4buznm5cpvlwwpoxtjeyisa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference